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In developed countries, right-sided infective 
endocarditis (RSIE) frequently complicates 
intravenous drug use (IDU) and retroviral disease 
(HIV).[1] RSIE has been rare in sub-Saharan Africa 
in both the pre- and post-HIV eras, probably owing 
to the low frequency of IDU.[2,3] We report three cases of RSIE seen at 
a single hospital. All the patients were HIV-positive and were abusers 
of intravenous nyoape. The purpose of this report is to to alert the 
medical community to a new pattern of disease in at-risk populations. 
Failure to detect RSIE early may result in poor long-term outcomes.
Case summaries
Three young HIV-positive men were referred from peripheral 
hospitals to Chris Hani Baragwanath Academic Hospital (CHBAH), 
Soweto, Johannesburg, South Africa (SA). None of the patients was 
on highly active antiretroviral therapy. All admitted to intravenous 
nyoape abuse.
Case 1
The first patient was 29 years old and presented with a 1-week history 
of fever, dyspnoea and features suggestive of right heart failure and 
severe tricuspid regurgitation (TR). He had tachycardia (136 bpm), was 
tachypnoeic (respiratory rate 30/min) and had normal blood pressure. 
He had a raised jugular venous pressure, a soft first heart sound and 
a 4/6 pansystolic murmur, typically loudest over the epigastrium 
and accentuated by manoeuvres that increase venous return. The 
liver was enlarged and pulsatile. No peripheral stigmata of infective 
endocarditis were noted. A chest radiograph showed an increased 
cardiothoracic index with an opacified right costophrenic angle. An 
initial electrocardiogram (ECG) revealed only sinus tachycardia.
Inflammatory markers were elevated (white cell count (WCC) 
18.7 × 109/L and C-reactive protein (CRP) 331 mg/L). The patient had 
a normochromic, normocytic anaemia (haemoglobin concentration 
9.7 g/dL). The CD4+ count was 576 cells/µL. Blood cultures revealed 
Escherichia coli and salmonella (both only on a single set of cultures).
Transthoracic echocardiography (TTE) demonstrated severe TR 
(Fig. 1) secondary to a flail anterior tricuspid leaflet. The left-sided 
valves were normal. Large oscillating masses were noted on the 
leaflets (the largest measuring 25 mm), extending to the subvalvular 
apparatus and periannular area (Fig. 2). The pulmonary valve was 
normal. The right ventricle (RV) was mildly enlarged with normal 
systolic function but abnormal diastolic function with initially 
normal systolic pulmonary artery pressure and later pulmonary 
hypertension. The latter finding could be attributed to pulmonary 
emboli (Fig. 3). The later ECG showed new T-wave inversion in the 
anterior leads indicative of RV pressure overload with ischaemia.
Definite tricuspid valve infective endocarditis (IE) was diagnosed 
based on the modified Duke criteria of one major criterion (oscillating 
masses on the valve leaflets) and three minor criteria (single positive 
blood cultures, IDU, fever (39°C) and suspected septic pulmonary 
emboli). A computed tomography pulmonary angiogram confirmed 
the presence of multiple bilateral pulmonary emboli complicated by 
infarction and cavitation.
The patient was commenced on treatment for IE, initially 
with gentamicin and cloxacillin. Five days later meropenem was 
substituted according to bacterial culture results. He also received 
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Fig. 1. Colour Doppler ultrasound scan showing severe tricuspid regurg itation.
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diuretics. The inflammatory markers declined (CRP to 28 mg/L and 
the WCC to 10 × 109/L). The patient was referred for debridement 
and bioprosthetic tricuspid valve replacement because of severe 
TR, large vegetation size (>20 mm) and persistent pulmonary 
embolisation despite adequate antibiotic therapy.
Case 2
The second patient was 30 years old and presented with subacute, 
progressive dyspnoea as the primary complaint. Findings on clinical 
and special investigations were similar to the first case. A diagnosis 
of definite tricuspid valve IE was made based on the modified Duke 
criteria with one major (oscillating valve mass) and four minor 
criteria (IDU, suspected septic pulmonary infarcts, fever and a typical 
micro-organism (Staphylococcus aureus) on one blood culture). The 
patient continued to embolise to the lungs despite antibiotic therapy, 
and there was no improvement in the right heart failure. The patient 
had a history of defaulting from treatment, absconded from the 
hospital while on antibiotic therapy, and showed poor insight. He was 
treated conservatively.
Case 3
The third patient, 20 years old, had a 3-week history of fever and 
vague chest and right upper quadrant pain. A diagnosis of possible 
tricuspid valve IE was made based on the modified Duke criteria 
with one major (oscillating valve mass) and three minor criteria 
(IDU, fever, suspected septic pulmonary infarcts). No organisms were 
cultured owing to prior antibiotic administration. The patient was 
empirically treated with intravenous vancomycin and gentamicin. 
The inflammatory markers improved, and he remained stable and 
was treated medically.
Discussion
To the best of our knowledge, these three cases are the first reported 
cases of RSIE secondary to intravenous nyoape use. Nyoape use is 
common in SA, especially among people from poor backgrounds.[4] 
Nyoape, also called whoonga or wunga, is a drug sold on the streets 
and has come to widespread use in SA since about 2010, initially 
among poor communities in Durban.[5] The ingredients are not 
exact or constant, but it usually contains an antiretroviral (ARV) 
such as efavirenz or ritonavir.[5] Other components include heroin, 
crystal methamphetamine, cannabis, cocaine and even rat poison.[5] 
Although nyoape was initially smoked, it is now being injected, as 
these cases suggest. This indicates a new pattern of drug use, which is 
likely to lead to an increase in cases of RSIE.
Heroin is the primary substance of abuse for 8% of individuals 
in treatment centres in Gauteng Province, SA. Nyoape is the most 
common form in which heroin is used by black South Africans, in 
particular, owing to its low cost. Users become addicted to the heroin 
component, but the neurological effects of efavirenz may play a role, 
as it is known to cause psychoactive symptoms.[5] ARVs may also 
potentiate the hypnotic effects of the other ingredients.[5] ARVs are 
sourced illegally from healthcare workers or are stolen from patients 
on ARVs.[5] This in turn may cause emergence of resistant HIV 
strains.[5]
IE affects right-sided valves in 5 - 10% of cases.[6] IE is most 
commonly seen in IDUs, especially in patients with concomitant 
HIV infection, as observed in our cases. The valve damage in RSIE 
is postulated to be secondary to poor hygiene in IDU, injection of 
contaminated matter or abnormalities of immune function.[6] The 
most common organism cultured is S. aureus, which accounts for 
60 - 90% of cases.[6] S. aureus was cultured in only one of our patients, 
possibly because treatment with antibiotics had been instituted at the 
referring hospitals prior to a diagnosis being established.
All our patients were HIV-positive, and the following aspects 
specific to HIV and IE should be taken into consideration when 
managing these patients. Cardiac surgery is not contraindicated 
in patients with concurrent HIV and IE.[7] There is no increase in 
complications and mortality postoperatively.[7] In general, patients 
with HIV and IDU tend to have involvement of the left-sided valves 
more commonly than the right-sided valves.[8] In HIV-infected IDUs, 
the most common causative organism is still S. aureus.[9,10] In HIV-
reactive (CD4+ count >350 cells/µL) IDUs, the odds ratio (OR) of 
developing IE is 2.31 compared with non-HIV-infected individuals. 
The OR increases to 8.31 at a CD4+ count of <350 cells/uL.[11] The 
mortality in patients with HIV and concomitant IE with a CD4+ 
count <200 cells/uL tends to be higher than in other groups.[12] More 
recent work, however, does not support the higher mortality in 
patients with low CD4+ counts.[10] There is no significant difference 
in terms of mortality and response to treatment with antimicrobials 
between HIV-infected and non-HIV-infected IDUs.[8,9,13,14]
A high level of suspicion needs to be maintained, as RSIE may 
present with nonspecific symptoms and lacks the usual peripheral 
stigmata associated with left-sided IE.[15] This results in delayed 
diagnosis and therapy of IE, as evident in all three of our cases. 
These cases highlight the importance of considering IE in a patient 
presenting with features suggestive of pneumonia coupled with right 
heart failure. Blood for culture (ideally three sets of cultures) should 
be drawn immediately in this context.
The more common complications of RSIE include fever and 
respiratory symptoms secondary to septic pulmonary emboli, as in 
Fig. 2. Modied apical four-chamber view showing multiple vegetations on 
the tricuspid valve (arrow) with a dilated right atrium and right ventricle.
Fig. 3. Multiple areas of consolidation suggestive of infarction and dilated 
right heart chambers on a computed tomography scan of the chest.
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our patients. Right-sided heart failure is uncommon. When it occurs, 
it is usually secondary to volume overload due to severe, organic TR 
or to pressure overload due to pulmonary hypertension caused by 
septic pulmonary emboli (or both).[6]
The diagnosis of IE on the tricuspid valve is made with TTE, 
which allows good visualisation of the valve because of its anterior 
location.[6] The overall sensitivity of TTE is 60 - 70%, but sensitivity 
increases to 80% in detection of right-sided endocarditis.[16] In 
most cases of RSIE, TTE is therefore sufficient. Transoesophageal 
echocardiography (TEE) is useful when the image quality is poor 
with TTE, TTE is negative in the presence of high clinical suspicion, 
or S. aureus septicaemia or a complication of IE is suspected.[6] The 
modified Dukes criteria are useful for the diagnosis of IE[6] but do not 
replace clinical judgement in cases where its sensitivity is reduced, 
such as in RSIE, especially in IDUs.[6]
The management of RSIE is largely conservative, with most 
cases treated medically. Empirical antibiotic treatment must cover 
S. aureus, for which vancomycin would be the drug of choice. The 
choice of empirical treatment will also be dictated by the suspected 
organism, IDU, and the valve involved.[6] Duration of antibiotic 
therapy ranges from 2 weeks in certain uncomplicated cases to up to 
6 weeks in complicated cases.[6]
Surgery is only considered in patients with intractable right-sided 
heart failure, unresponsive to heart failure treatment in the form of 
diuretics; difficult-to-eliminate organisms; persistent bacteraemia 
(minimum of 1 week’s duration), despite appropriate antibiotics; 
and large tricuspid valve vegetations of ≥2 cm that persist and are 
complicated by recurrent embolisation to the lung, in the presence 
or absence of right heart failure.[6] Our first patient was referred for 
surgery because of recurrent pulmonary emboli with worsening 
pulmonary hypertension, despite being on appropriate antibiotic 
therapy.
The goal of surgery in RSIE is to achieve complete debridement 
of the infected tissue, and preferably valve repair. If repair is not 
feasible owing to extensive valve destruction, valve replacement with 
a bioprosthetic valve should be undertaken. A simple valvectomy, 
as advocated traditionally, may result in worsening of right-sided 
haemodynamics postoperatively, if pulmonary hypertension has been 
present preoperatively.[6]
Lastly, the second patient with poor insight constitutes an ethical 
dilemma regarding conservative v. surgical treatment, especially in a 
resource-limited setting. From the limited available literature, surgery 
should be offered for the first episode of IE in IDUs who are willing to 
undergo rehabilitation. If the patient presents with a second episode 
of IE secondary to lack of compliance, he or she should probably not 
qualify for further surgical intervention.[17]
Since the time of writing, an additional three cases with a similar 
presentation have been seen.
Conclusion
We are likely to encounter more cases of RSIE secondary to 
intravenous nyoape use with concurrent HIV infection. A high level 
of vigilance should be maintained and diagnosis made early before 
complications arise.
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